Euradal en es it fr

Euradal Brand names, Euradal Analogs

Euradal Brand Names Mixture

  • Ziac (bisoprolol + hydrochlorothiazide)

Euradal Chemical_Formula


Euradal RX_link

Euradal fda sheet

Euradal msds (material safety sheet)

Euradal MSDS

Euradal Synthesis Reference

R. Jonas et al.;U.S. pat. 4,258,062 (1978,1981)

Euradal Molecular Weight

325.443 g/mol

Euradal Melting Point

100 oC

Euradal H2O Solubility

2240 mg/L

Euradal State


Euradal LogP


Euradal Dosage Forms

Tablets (5 and 10 mg)

Euradal Indication

For the management of hypertension and prophylaxis treatment of angina pectoris and heart failure.

Euradal Pharmacology

Bisoprolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Bisoprolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as Bisoprolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.

Euradal Absorption


Euradal side effects and Toxicity

Oral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.

Euradal Patient Information

Patients especially those with coronary artery disease should be warned about discontinuing use of ZEBETA without a physician's supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia.

Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia, and bisoprolol fumarate should be used with caution. Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness.

Euradal Organisms Affected

Humans and other mammals